Published by Josh White on 22nd December 2025
(Sharecast News) - AstraZeneca on Monday reported mixed regulatory and clinical news, with its breast cancer drug Enhertu securing a US breakthrough therapy designation in early disease, while a late-stage lung cancer trial of ceralasertib in combination with Imfinzi failed to meet its primary survival endpoint.